

## Information from June 8<sup>th</sup>, 2023 Quarterly Provider Meeting

### Xylazine and Harm Reduction

Michele Calvo, Director, Opioid Response and Policy  
NJ Department of Health

[Knock out Opioid Use Day](#) – Learning Series, Presentation by Dr. Haroz

“The Rise of Poly-Substance Overdose Deaths”

***“Warning: This PowerPoint contains graphic images of wounds caused by Xylazine”***

Slide presentation [PowerPoint Presentation \(drugfreenj.org\)](#)

Xylazine or "tranq", is becoming increasingly more prevalent in the illicit drug supply throughout the United States. Xylazine is a veterinary tranquilizer that is not approved for human use and is not an opioid. On April 12, 2023, the White House Office of National Drug Control Policy (ONDCP) officially designated fentanyl adulterated or associated with xylazine as an emerging threat to the United States and it is increasingly identified in New Jersey’s drug supply.

[XYLAZINE: What to Know \(nj.gov\)\\_English](#)

[XYLAZINE: What to Know \(nj.gov\)\\_Spanish](#)

[Health Alert: Xylazine in the New Jersey Illicit Drug Supply](#)

---

### Harm Reduction Centers

Greta Anschuetz, Assistant Commissioner  
Division of HIV, STD and TB Services  
NJ Department of Health

Law for Harm Reduction: N.J.S.A 26:5C-25-29 (statute)

[Section 26:5C-27 - Operation of sterile syringe access program, N.J. Stat. § 26:5C-27 | Casetext Search + Citator](#)

Harm Reduction Center Rules <https://www.nj.gov/health/hivstdtb/hrc/>

Harm Reduction Center Registration Application <https://www.nj.gov/health/forms/hrc-1.pdf>

---

[New Jersey Overdose Data Dashboard](#)